Evidence map›Paper›PMID 37400888›Full record

ArticleAlzheimer's research & therapy2023

Plasma apolipoprotein E levels, isoform composition, and dimer profile in relation to plasma lipids in racially diverse patients with Alzheimer's disease and mild cognitive impairment.

Andreas Giannisis, Asma Al-Grety, Henrik Carlsson, Jennifer C Howell, William T Hu, Kim Kultima, Henrietta M Nielsen

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Alzheimer's research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Observational
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Andreas GiannisisDepartment of Biochemistry and Biophysics, Stockholm University, Svante Arrhenius Väg 16B, 114 18, Stockholm, Sweden.
Asma Al-GretyDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden.
Henrik CarlssonDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden.
Jennifer C HowellDepartment of Neurology, Emory University, Atlanta, GA, USA.
William T HuDepartment of Neurology, Emory University, Atlanta, GA, USA.
Kim KultimaDepartment of Medical Sciences, Clinical Chemistry, Uppsala University, Uppsala, Sweden.
Henrietta M NielsenDepartment of Biochemistry and Biophysics, Stockholm University, Svante Arrhenius Väg 16B, 114 18, Stockholm, Sweden. henrietta.nielsen@dbb.su.se.
Uppsala University · SEStockholm University · SEEmory University · USJohnson University · US

Funding

CSF, MRI, and PET biomarkers of neuroinflammation in Alzheimer's diseaseR01AG054046 · NIA · RBHS-ROBERT WOOD JOHNSON MEDICAL SCHOOL · PI HU, WILLIAM TZU-LUNG · 2016 to 2020
$3.9M
Role of estradiol and related hormones on inflammation, sleep, and risks for Alzheimer's diseaseR01AG066203 · NIA · EMORY UNIVERSITY · PI HU, WILLIAM TZU-LUNG, WHARTON, WHITNEY LEE · 2019 to 2023
$3.6M
African American Alzheimer's Progression Markers - CSF and Neuro-ImagingR21AG043885 · NIA · EMORY UNIVERSITY · PI HU, WILLIAM TZU-LUNG · 2013 to 2014
$429k
NIA NIH HHS R01 AG054046NIA NIH HHS R01 AG066203NIA NIH HHS R21 AG043885
6 · The paper itself

Abstract

backgroundThe APOEε4-promoted risk of Alzheimer's disease (AD) is lower in Black/African-Americans (B/AAs), compared to non-Hispanic whites (NHWs). Previous studies reported lower plasma apolipoprotein E (apoE) levels in NHW APOEε4-carriers compared to non-carriers, and low plasma apoE levels were directly associated with an increased risk of AD and all dementia. We further showed that APOEε3/ε3 AD patients exhibited reduced plasma apoE dimers compared to corresponding control subjects. Whether plasma apoE levels and apoE dimer formation differ between races/ethnicities and therefore may help explain AD risk racial disparity remains to be elucidated.

methodsUsing mass spectrometry, we determined total plasma apoE and apoE isoform levels in a cohort of B/AAs (n = 58) and NHWs (n = 67) including subjects with normal cognition (B/AA: n = 25, NHW: n = 28), mild cognitive impairment (MCI) (B/AA: n = 24, NHW: n = 24), or AD dementia (B/AA: n = 9, NHW: n = 15). Additionally, we used non-reducing western blot analysis to assess the distribution of plasma apoE into monomers/disulfide-linked dimers. Plasma total apoE, apoE isoform levels, and % apoE monomers/dimers were assessed for correlations with cognition, cerebrospinal fluid (CSF) AD biomarkers, sTREM2, neurofilament light protein (NfL), and plasma lipids.

resultsPlasma apoE was predominantly monomeric in both racial groups and the monomer/dimer distribution was not affected by disease status, or correlated with CSF AD biomarkers, but associated with plasma lipids. Plasma total apoE levels were not related to disease status and only in the NHW subjects we observed lower plasma apoE levels in the APOEε4/ε4-carriers. Total plasma apoE levels were 13% higher in B/AA compared to NHW APOEε4/ε4 subjects and associated with plasma high-density lipoprotein (HDL) in NHW subjects but with low-density lipoprotein levels (LDL) in the B/AA subjects. Higher plasma apoE4 levels, exclusively in APOEε3/ε4 B/AA subjects, were linked to higher plasma total cholesterol and LDL levels. In the controls, NHWs and B/AAs exhibited opposite associations between plasma apoE and CSF t-tau.

conclusionsThe previously reported lower APOEε4-promoted risk of AD in B/AA subjects may be associated with differences in plasma apoE levels and lipoprotein association. Whether differences in plasma apoE levels between races/ethnicities result from altered APOEε4 expression or turnover, needs further elucidation.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAmyloid beta-PeptidesApolipoprotein E4Apolipoproteins EBiomarkersBlack or African AmericanHumansNeurofilament ProteinsProtein Isoformstau ProteinsWhiteAmyloid beta-PeptidesApolipoprotein E4Apolipoproteins EBiomarkersNeurofilament ProteinsProtein Isoformstau ProteinsAlzheimer’s diseaseAPOEε4Apolipoprotein EBlack/African-AmericansPlasma

Identifiers

PMID37400888
PMCPMC10316569
OpenAlexW4382987220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.